

DR4 antibodies, 4E7.24.3 and 4H6.17.8, to DR4 and to other known Apo-2L receptors referred to as Apo-2, DcR1, and DcR2.---

In the paragraph on page 8, lines 15-17, the text has been amended to read:

-Figures 9A-9B show apoptotic activity of DR4 antibodies, 4H6, 4E7, 4G7, 4G10.20.6 ("4G10"), 3G1.17.2 ("3G1"), 5G11, 1H8.17.5 ("1H8"), and 1H5.24.9 ("1H5") on SKMES colon tumor cells in the presence of goat anti-mouse IgG Fc. ---

IN THE CLAIMS:

Please amend claim 1 to read:

1. (Twice Amended) An isolated antibody which specifically binds to DR4 polypeptide comprising amino acid residues 24 to 218 of Figure 1 (SEQ ID NO:2).
2. The antibody of Claim 1 which is an agonist antibody.
3. The antibody of Claim 1 which is a blocking antibody.
4. The antibody of Claim 1 which is a monoclonal antibody.
5. The antibody of Claim 1 which is a murine antibody.
6. The antibody of Claim 1 which is a humanized antibody.
7. The antibody of Claim 1 which is a chimeric antibody.
8. The antibody of Claim 1 which is a monomeric antibody.
9. The antibody of Claim 1 which is a multivalent antibody.
10. A hybridoma cell line which produces the antibody of Claim 4.

Please amend claim 11 to read:

11. (Twice Amended) An isolated monoclonal antibody which specifically binds to DR4 polypeptide comprising amino acid residues 24 to 218 of Figure 1 (SEQ ID NO:2) and which has the same biological characteristics of (1) the monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC HB-12695; (2) the monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC HB-12694; or (3) the monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC PTA-99.

Please amend claim 12 to read:

12. (Twice Amended) An isolated monoclonal antibody which specifically binds to DR4 polypeptide comprising amino acid residues 24 to 218 of Figure 1 (SEQ ID NO:2) and which binds to the same epitope as (1) the epitope to which the monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC HB-12695 binds; (2) the epitope to which the monoclonal antibody produced by the hybridoma cell line deposited under the American Type Culture Collection Accession Number ATCC HB-12694 binds; or (3) the epitope to which the monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC PTA-99 binds.
13. The hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC HB-12695.
14. The hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC HB-12694.
15. The hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC PTA-99.
16. The monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC HB-12695.
17. The monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC HB-12694.
18. The monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Accession Number ATCC PTA-99.
20. A composition comprising the antibody of Claim 1 and a carrier.
21. The composition of claim 20 wherein said carrier is a pharmaceutically acceptable carrier.
23. (Once Amended) An article of manufacture, comprising a container and a composition contained within said container, wherein the composition includes the DR4 antibody of claim 1.
24. The article of manufacture of Claim 23 further comprising instructions for using the DR4 antibody *in vivo* or *ex vivo*.

Please amend claim 33 to read:

33. (Once Amended) An isolated antibody which binds to DR4 polypeptide comprising amino acid residues 24 to 218 of Figure 1 (SEQ ID NO:2) and which induces apoptosis in at least one type of mammalian cancer cell.
34. The antibody of Claim 33 which is a monoclonal antibody.
35. The antibody of Claim 33 which is a human antibody.
36. The antibody of Claim 33 which is a humanized antibody.
37. The antibody of Claim 33 which is a chimeric antibody.
38. The antibody of Claim 33 wherein said mammalian cancer cell expresses DR4 polypeptide.
39. The antibody of Claim 33 wherein said mammalian cancer cell is a lung cancer cell.
40. The antibody of Claim 33 wherein said mammalian cancer cell is a colon cancer cell.
41. The antibody of Claim 33 which is cross-linked to a homologous DR4 antibody.

Please amend claim 42 to read:

42. (Once Amended) An isolated antibody which binds to DR4 polypeptide comprising amino acid residues 24 to 218 of Figure 1 (SEQ ID NO:2) and which blocks binding of Apo-2 ligand to said DR4 polypeptide.
43. The antibody of Claim 42 which is a monoclonal antibody.
44. The antibody of Claim 42 which is a human antibody.
45. The antibody of Claim 42 which is a humanized antibody.
46. The antibody of Claim 42 which is a chimeric antibody.

Please amend claim 47 to read:

47. (Once Amended) An isolated antibody which binds to DR4 polypeptide comprising amino acid residues 24 to 218 of Figure 1 (SEQ ID NO:2) and which blocks Apo-2 ligand induced apoptosis in at least one type of mammalian cancer cell.
48. The antibody of Claim 47 which is a monoclonal antibody.
49. The antibody of Claim 47 which is a human antibody.
50. The antibody of Claim 47 which is a humanized antibody.
51. The antibody of Claim 47 which is a chimeric antibody.
52. The antibody of Claim 47 wherein said mammalian cancer cell expresses DR4 polypeptide.

53. The antibody of Claim 47 wherein said mammalian cancer cell is a lung cancer cell.

54. The antibody of Claim 47 wherein said mammalian cancer cell is a colon cancer cell.

55. The antibody of Claim 47 which is cross-linked to a homologous DR4 antibody.